| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
- R112
-
- $76.00
-
2026-07-27
- CAS:575474-82-7
- Purity: 99.65%
- Supply Ability: 10g
|
| | R 112 (pharMaceutical) Basic information |
| Product Name: | R 112 (pharMaceutical) | | Synonyms: | R 112 (pharMaceutical);Phenol, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis-;(E)-Elafibranor;3,3'-[(5-Fluoro-2,4-pyrimidinediyl)diimino]diphenol;R-112; R 112;R112, >98%;Spleen tyrosine kinase,allergic rhinitis,R112,fast,tryptase,Inhibitor,R 112,phosphorylation,IL-8,GM-CSF,histamine,LTC4,reversible,basophil,R-112,TNF-α,Syk,inhibit;3,3'-((5-Fluoropyrimidine-2,4-diyl)bis(azanediyl))diphenol | | CAS: | 575474-82-7 | | MF: | C16H13FN4O2 | | MW: | 312.3 | | EINECS: | | | Product Categories: | | | Mol File: | 575474-82-7.mol |  |
| | R 112 (pharMaceutical) Chemical Properties |
| Boiling point | 552.0±60.0 °C(Predicted) | | density | 1.494±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:30.0(Max Conc. mg/mL);96.1(Max Conc. mM) | | form | A crystalline solid | | pka | 9.48±0.10(Predicted) | | color | Light yellow to yellow |
| | R 112 (pharMaceutical) Usage And Synthesis |
| Description | R112 is an inhibitor of spleen tyrosine kinase (Syk; IC50 = 226 nM in cultured human mast cells) that acts in an ATP-competitive and reversible manner (Ki = 96 nM). It inhibits mast cell and basophil degranulation induced by anti-IgE cross-linking (EC50s = 353 and 280 nM, respectively). It also inhibits basophil degranulation induced by an allergen with an EC50 value of 490 nM. R112 inhibits the production of leukotriene C4 (LTC4; ) and decreases cytokine levels in cultured human mast cells. | | Uses | R 112 is Syk inhibitor. It can be used in biological study and therapeutic use of application of cultured human mast cells (CHMC) for design and structure-activity relationship of IgE-mediated mast cell activation inhibitors. | | References | [1] ALEXANDER B. ROSSI BA. Identification of the Syk kinase inhibitor R112 by a human mast cell screen[J]. Journal of Allergy and Clinical Immunology, 2006, 118 3: Pages 749-755. DOI: 10.1016/j.jaci.2006.05.023 |
| | R 112 (pharMaceutical) Preparation Products And Raw materials |
|